Form 4: Boston Scientific EVP John Bradley Sorenson Reports Stock Transactions

John Bradley Sorenson, EVP of Global Operations at Boston Scientific, reports the vesting of restricted stock units and subsequent sale of shares under a pre-established trading plan.

Summary

• On May 2, 2025, John Bradley Sorenson, EVP of Global Operations at Boston Scientific, had 4,204 restricted stock units vest, each representing one share of Boston Scientific common stock.
• Also on May 2, 2025, Sorenson disposed of 1,918 shares to cover tax obligations at a price of $104.93 per share.
• On May 5, 2025, Sorenson sold 4,572 shares of common stock at a price of $104.54 per share.
• Following these transactions, Sorenson directly owns 18,705 shares of Boston Scientific common stock and 4,204 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It is common for executives to have pre-established trading plans to manage their stock holdings and avoid any appearance of trading on inside information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies like Boston Scientific and are comparable to filings made by executives at similar medical device companies such as Medtronic, Abbott Laboratories, and Stryker.
• The use of Rule 10b5-1 trading plans is also a common practice among executives to automate stock sales and comply with insider trading regulations, similar to practices seen at other large corporations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive, but the pre-established trading plan mitigates concerns about insider trading.
• The vesting of restricted stock units and subsequent sale of shares could have a slight dilutive effect on existing shareholders.

Key Dates

Keywords

Form 4, insider trading, stock sale, restricted stock units, John Bradley Sorenson, Boston Scientific, BSX